Bio Rad Labs Inc SEC Filings

Bio‑Rad Laboratories (BIO) executive Sedat Evran (EVP, Global Supply Chain) reported routine equity vesting. On 10/20/2025, 1,044 restricted stock units converted into Class A common stock at $0 per the award terms, and 335 shares were withheld at $321.90 to cover taxes. Following these transactions, Evran beneficially owned 2,232.847 Class A shares.

The RSUs relate to a grant of 4,176 units made on 10/20/2023, vesting in four equal annual installments beginning on the first anniversary of the grant date.

BlackRock, Inc. filed an amended Schedule 13G (Amendment No. 12) reporting beneficial ownership of 1,618,123 shares of Bio‑Rad Laboratories, Inc. Class A stock, representing 7.4% of the class.

BlackRock reports sole voting power over 1,561,852 shares and sole dispositive power over 1,618,123 shares, with 0 shared voting or dispositive power. The date of event triggering the filing is 09/30/2025. BlackRock certifies the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.

Evran Sedat, Executive Vice President, Global Supply Chain at Bio-Rad Laboratories (BIO), reported insider transactions on a Form 4 covering September 5–6, 2025. The filing shows vesting and purchases that increased his direct holdings and a small sale. Specifically, 4,110 restricted stock units vested on 09/05/2025 and were converted into 4,110 shares. On 09/06/2025 an additional 864 restricted stock units vested and were converted into 864 shares. The report also lists purchases under the Employee Stock Purchase Plan earlier in 2025 totaling 83.707 shares (56.9880 and 26.7190) and a disposition of 277 shares sold at $295.43.

The transactions are reported as direct holdings and reflect routine equity compensation vesting and periodic ESPP participation, with the sale reducing holdings by 277 shares to 1,523.847 shares following the reported sale.

Roop K. Lakkaraju, EVP and Chief Financial Officer of Bio-Rad Laboratories (BIO), reported insider transactions on Form 4. The filing shows restricted stock units vesting and resulting share acquisitions and a separate disposition. On 09/05/2025, 5,480 restricted stock units vested and were acquired at $0 per unit. On 09/06/2025, 1,535 shares were acquired (noted as transaction code M) at $0 and the report records a disposition of 550 shares sold on 09/06/2025 at $295.43. The filing states the reporting person beneficially owned 2,393.659 shares following the 09/06 acquisition and 1,843.659 shares after the 550-share disposition. The filing also notes inclusion of 13.2750 shares acquired under the Bio-Rad Employee Stock Purchase Plan on 06/30/2025. All transactions are reported as direct beneficial ownership.

Colleen Corey, EVP Global Human Resources at Bio-Rad Laboratories (BIO), reported stock award vesting and a small sale. On 09/05/2025 Ms. Corey received 2,740 restricted stock units (each convertible to one share) that vest over four years at 25% per year. On 09/06/2025 she acquired an additional 576 shares on vesting and sold 209 shares at $295.43 per share. Following these transactions she beneficially owned 19,759 shares of Bio-Rad Class A common stock (direct) for non-derivative holdings and 2,740 RSUs shown as derivative holdings.

Bio-Rad Laboratories insider change: Barry James, EVP and President, LSG, reported acquisition and disposition activity on 09/05–09/06/2025. On 09/05/2025 4,110 restricted stock units (each convertible into one Class A share) vested, and 4,110 shares are shown as beneficially owned following that vesting. On 09/06/2025 an additional 1,056 restricted stock units were recorded as acquired via vesting, increasing the reported RSU-derived holdings. The Form 4 also shows a separate transaction on 09/06/2025 with code F disposing of 378 shares at $295.43 per share. Following the transactions, the filing reports 1,587.555 and 1,209.555 shares in two non-derivative lines and 4,110 and 3,168 RSU-derived shares in derivative lines as beneficially owned in the respective entries.

Allison Schwartz, a director of Bio-Rad Laboratories (BIO), reported transactions on Form 4 reflecting the vesting of restricted stock units and a small sale of common stock. On 09/05/2025 she received 914 restricted stock units that vested, each convertible into one share, increasing her derivative-based holdings to 914 units. On 09/06/2025 an additional 92 shares were recorded as acquired on vesting and 33 shares were sold at a price of $295.43 each. After the reported transactions her direct beneficial ownership in Class A common stock is shown as 1,489 shares on 09/06/2025 and 1,456 shares following the sale. The filing documents the standard four-year vesting schedule for the RSUs at 25% per year.

Jonathan P. DiVincenzo, President & COO of Bio-Rad Laboratories, acquired 6,850 restricted stock units (RSUs) on 09/05/2025, each representing a contingent right to one share of Bio-Rad Class A common stock. The RSUs were granted with a $0 per-unit price and vest over four years at 25% per year on each annual anniversary of the grant. Following the transaction, DiVincenzo beneficially owns 6,850 shares subject to these RSUs, held directly. The Form 4 was signed on 09/08/2025. No other derivatives or dispositions are reported in this filing.